The Successful Story Of Biotech Finding COVID-19 Vaccine

Biotech and Ganymed Centre in Mainz: Eveline Lemke with Özlem Türeci and Uğur Şahin / Georg Banek  Biotech is not only the world-famous sup...

Biotech and Ganymed Centre in Mainz: Eveline Lemke with Özlem Türeci and Uğur Şahin / Georg Banek 

Biotech is not only the world-famous supplier of the hopefully saving corona vaccine, but it is a successful experiment ever done by humans saving the world from a cataclysmic manifestation and collapse.  Vaccine's research's a great job done by the working group of Prof. Dr. Uğur Şahin and Prof. Dr. Özlem Türeci at the Mainz University Medical Center in Rhineland, Germany. 

Şahin and Türeci continue to do basic research for new ways to fight cancer at the university. "If we want to achieve something for the patient, it is not enough that we are medical professionals ," Türeci once told the university magazine . "We are wanderers between worlds: we also have to be entrepreneurs, engineers, IT specialists, and much more."

Therefore, the two founded the company Ganymed, which was sold to the Japanese pharmaceutical company Astellas with a new gastric cancer drug in the pipeline. Biotech was the next step in developing customized cancer therapies using mRNA technology. That the same technology is also suitable for mass vaccination against Covid-19 - research spirit. That the project succeeds - entrepreneurship. 

The cooperation with the US company Pfizer helped achieve the commercial breakthrough. If its prognosis is correct, the vaccine Comirnaty should become the top-selling drug in the world this year. Biotech, traded on the New York technology exchange Nasdaq with a value of 24 billion euros, could deal with the inflow of money according to the will of investors Establish it as an independent pharmaceutical company - and ultimately bring the novel cancer therapy onto the market.